Top

Quality of Life Research

Published in:

02-03-2021

Health state utility and quality of life measures in patients with chronic myeloid leukemia in France

Authors: Foulon S, Cony-Makhoul P, Guerci-Bresler A, Daban M, Kapso R, Tubert-Bitter P, Bonastre J

Published in: Quality of Life Research | Issue 7/2021

Activate our intelligent search to find suitable subject content or patents.

search-config

AI-assisted search

Off

Abstract

Purpose

Tyrosine kinase inhibitors (TKIs) have dramatically improved the prognosis of chronic myeloid leukemia (CML). We aimed to assess health state utility and quality of life (QoL) in French patients with CML in real-life setting, to study the determinants of utility score and to compare health-related QoL values to general population norms.

Methods

We conducted a cross-sectional study in 412 patients with CML. Data were collected by electronic survey. Three patient-reported outcomes questionnaires were used: EORTC QLQ-C30, EORTC QLQ-CML24 and EuroQol EQ-5D-3L. Health state utility values were computed using the French value set. We computed deviations from reference norms from the general population. We studied the determinants of health utility score using multiple regression models.

Results

The mean utility score (SD) was 0.72 (0.25) in the chronic phase and 0.84 (0.21) in treatment-free remission, with marked variations by gender. Patients with CML had a deviation from the reference norm of −0.15 on average (SD: 0.25). In terms of QoL, social functioning, role functioning and cognitive functioning were notably impacted with a mean difference of −16.0, −13.1 and −11.7 respectively. Fatigue, dyspnea and pain were the symptoms with the highest deviation from general population norms (mean difference of 20.6, 14.0 and 8.3 respectively). In the multiple regression analysis, fatigue was the most important independent predictor of the utility score.

Conclusion

Although TKIs prevent the disease from progressing and even allow remission without treatment, QoL in patients with CML is notably altered. The utility scores deteriorate with CML symptoms.

previous article Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D

next article Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Available only for authorised users

Apperley, J. F. (2015). Chronic myeloid leukaemia. Lancet (London, England), 385(9976), 1447–1459. https://doi.org/10.1016/S0140-6736(13)62120-0.CrossRef

Le Guyader-Peyrou, S., Belot, A., Maynadié, M., Binder-Foucard, F., Remontet, L., Troussard, X., et al. (2016). Cancer incidence in France over the 1980–2012 period: Hematological malignancies. Revue D’epidemiologie Et De Sante Publique, 64(2), 103–112. https://doi.org/10.1016/j.respe.2015.12.017.CrossRefPubMed

Höglund, M., Sandin, F., & Simonsson, B. (2015). Epidemiology of chronic myeloid leukaemia: An update. Annals of Hematology, 94(Suppl 2), S241-247. https://doi.org/10.1007/s00277-015-2314-2.CrossRefPubMed

Foulon, S., Cony-Makhoul, P., Guerci-Bresler, A., Delord, M., Solary, E., Monnereau, A., et al. (2019). Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study. Cancer Medicine, 8(6), 3296–3304. https://doi.org/10.1002/cam4.2200.CrossRefPubMedPubMedCentral

Bower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T.M.-L. (2016). Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 34(24), 2851–2857. https://doi.org/10.1200/JCO.2015.66.2866.CrossRef

Mahon, F.-X. (2017). Treatment-free remission in CML: Who, how, and why? Hematology American Society of Hematology. Education Program, 2017(1), 102–109. https://doi.org/10.1182/asheducation-2017.1.102.CrossRefPubMedPubMedCentral

Rea, D., Ame, S., Berger, M., Cayuela, J.-M., Charbonnier, A., Coiteux, V., et al. (2018). Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer, 124(14), 2956–2963. https://doi.org/10.1002/cncr.31411.CrossRefPubMed

Efficace, F., & Cannella, L. (2016). The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology American Society of Hematology Education Program, 2016(1), 170–179. https://doi.org/10.1182/asheducation-2016.1.170.CrossRefPubMedPubMedCentral

Hahn, E. A., Glendenning, G. A., Sorensen, M. V., Hudgens, S. A., Druker, B. J., Guilhot, F., et al. (2003). Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 21(11), 2138–2146. https://doi.org/10.1200/JCO.2003.12.154.CrossRef

10.

Trask, P. C., Cella, D., Besson, N., Kelly, V., Masszi, T., & Kim, D.-W. (2012). Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leukemia Research, 36(4), 438–442. https://doi.org/10.1016/j.leukres.2011.10.011.CrossRefPubMed

11.

Whiteley, J., Reisman, A., Shapiro, M., Cortes, J., & Cella, D. (2016). Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Current Medical Research and Opinion, 32(8), 1325–1334. https://doi.org/10.1185/03007995.2016.1174108.CrossRefPubMed

12.

Park, J. S., Lee, S.-E., Jeong, S. H., Jang, E.-J., Choi, M.-Y., Kim, H.-J., et al. (2016). Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. Leukemia & Lymphoma, 57(2), 341–347. https://doi.org/10.3109/10428194.2015.1049166.CrossRef

13.

Efficace, F., Castagnetti, F., Martino, B., Breccia, M., D’Adda, M., Angelucci, E., et al. (2018). Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. Cancer, 124(10), 2228–2237. https://doi.org/10.1002/cncr.31323.CrossRefPubMed

14.

Efficace, F., Stagno, F., Iurlo, A., Breccia, M., Cottone, F., Bonifacio, M., et al. (2020). Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia, 34(2), 488–498. https://doi.org/10.1038/s41375-019-0563-0.CrossRefPubMed

15.

Efficace, F., Baccarani, M., Breccia, M., Alimena, G., Rosti, G., Cottone, F., et al. (2011). Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood, 118(17), 4554–4560. https://doi.org/10.1182/blood-2011-04-347575.CrossRefPubMed

16.

Phillips, K. M., Pinilla-Ibarz, J., Sotomayor, E., Lee, M. R., Jim, H. S. L., Small, B. J., et al. (2013). Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A controlled comparison. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 21(4), 1097–1103. https://doi.org/10.1007/s00520-012-1630-5.CrossRef

17.

Reed, S. D., Anstrom, K. J., Ludmer, J. A., Glendenning, G. A., & Schulman, K. A. (2004). Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 101(11), 2574–2583. https://doi.org/10.1002/cncr.20694.CrossRefPubMed

18.

Labeit, A. M., Copland, M., Cork, L. M., Hedgley, C., Foroni, L., Osborne, W. L., et al. (2015). Assessment of quality of life in the NCRI spirit 2 study comparing imatinib with dasatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia. Blood, 126(23), 4024.CrossRef

19.

Szabo, S. M., Levy, A. R., Davis, C., Holyoake, T. L., & Cortes, J. (2010). A multinational study of health state preference values associated with chronic myelogenous leukemia. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 13(1), 103–111. https://doi.org/10.1111/j.1524-4733.2009.00573.x.CrossRef

20.

Guest, J. F., Naik, N., Sladkevicius, E., Coombs, J., & Gray, E. J. (2012). Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom. Leukemia & Lymphoma, 53(5), 928–933. https://doi.org/10.3109/10428194.2011.631155.CrossRef

21.

Guest, J. F., Gray, E. J., Szczudlo, T., & Magestro, M. (2014). Utility values for specific chronic myeloid leukemia chronic phase health states from the general public in the United Kingdom. Leukemia & Lymphoma, 55(8), 1870–1875. https://doi.org/10.3109/10428194.2013.854886.CrossRef

22.

EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy (Amsterdam, Netherlands), 16(3), 199–208.CrossRef

23.

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRef

24.

Efficace, F., Baccarani, M., Breccia, M., Saussele, S., Abel, G., Caocci, G., et al. (2014). International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: The EORTC QLQ-CML24. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 23(3), 825–836. https://doi.org/10.1007/s11136-013-0523-5.CrossRef

25.

Chevalier, J., & de Pouvourville, G. (2013). Valuing EQ-5D using time trade-off in France. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care, 14(1), 57–66. https://doi.org/10.1007/s10198-011-0351-x.CrossRefPubMed

26.

Efficace, F., Iurlo, A., Patriarca, A., Stagno, F., Bee, P.-C., Ector, G., et al. (2020). Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leukemia & Lymphoma. https://doi.org/10.1080/10428194.2020.1838509.CrossRef

27.

Szende, A., Janssen, B., & Cabases, J. (2014). Self-reported population health: An international perspective based on EQ-5D. Netherlands: Springer.CrossRef

28.

Liegl, G., Petersen, M. A., Groenvold, M., Aaronson, N. K., Costantini, A., Fayers, P. M., et al. (2019). Establishing the European Norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core. European Journal of Cancer (Oxford, England: 1990), 107, 133–141. https://doi.org/10.1016/j.ejca.2018.11.023.CrossRef

29.

Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2011). Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29(1), 89–96. https://doi.org/10.1200/JCO.2010.28.0107.CrossRef

30.

Coretti, S., Ruggeri, M., & McNamee, P. (2014). The minimum clinically important difference for EQ-5D index: A critical review. Expert Review of Pharmacoeconomics & Outcomes Research, 14(2), 221–233. https://doi.org/10.1586/14737167.2014.894462.CrossRef

31.

Pickard, A. S., Neary, M. P., & Cella, D. (2007). Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health and Quality of Life Outcomes, 5, 70. https://doi.org/10.1186/1477-7525-5-70.CrossRefPubMedPubMedCentral

32.

Kvam, A. K., Fayers, P. M., & Wisloff, F. (2011). Responsiveness and minimal important score differences in quality-of-life questionnaires: A comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. European Journal of Haematology, 87(4), 330–337. https://doi.org/10.1111/j.1600-0609.2011.01665.x.CrossRefPubMed

33.

Kulpeng, W., Sompitak, S., Jootar, S., Chansung, K., & Teerawattananon, Y. (2014). Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. Clinical Therapeutics, 36(4), 534–543. https://doi.org/10.1016/j.clinthera.2014.02.008.CrossRefPubMed

34.

Arnold, D., Girling, A., Stevens, A., & Lilford, R. (2009). Comparison of direct and indirect methods of estimating health state utilities for resource allocation: Review and empirical analysis. BMJ (Clinical Research Esd.), 339, b2688. https://doi.org/10.1136/bmj.b2688.CrossRef

35.

Devlin, N. J., & Brooks, R. (2017). EQ-5D and the EuroQol Group: Past, Present and Future. Applied Health Economics and Health Policy, 15(2), 127–137. https://doi.org/10.1007/s40258-017-0310-5.CrossRefPubMedPubMedCentral

36.

Zulbaran-Rojas, A., Lin, H.-K., Shi, Q., Williams, L. A., George, B., Garcia-Manero, G., et al. (2018). A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Medicine, 7(11), 5457–5469. https://doi.org/10.1002/cam4.1808.CrossRefPubMedPubMedCentral

Title: Health state utility and quality of life measures in patients with chronic myeloid leukemia in France
Authors: Foulon S
Cony-Makhoul P
Guerci-Bresler A
Daban M
Kapso R
Tubert-Bitter P
Bonastre J
Publication date: 02-03-2021
Publisher: Springer International Publishing
Published in: Quality of Life Research / Issue 7/2021
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-021-02794-5

Springer Professional

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to your license.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Wirtschaft"

Other articles of this Issue 7/2021

The association between diabetic complications and health-related quality of life in patients with type 2 diabetes: a cross-sectional study from Iran

Moving beyond family: unequal burden across mental health patients’ social networks

Comparing the measurement properties of the EQ-5D-5L and the EQ-5D-3L in hypertensive patients living in rural China

Mental component of health-related quality of life is an independent predictor of incident functional disability among community-dwelling older people: a prospective cohort study

Psychometric properties of the Patient-Reported Outcomes Measurement Information System (PROMIS®) pediatric item bank peer relationships in the Dutch general population

What’s important when caring for a loved one? Population-based preference weights for the Adult Social Care Outcomes Toolkit for informal carers (ASCOT-Carer) for Austria